The UK-based company's lead compound is milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases involved in cell division as well as a number of other protein kinases. It is also advancing foralumab, the only fully human engineered anti-human CD3 antibody in clinical development.